CASI Pharmaceuticals Inc. (CASI)
(Delayed Data from NSDQ)
$5.53 USD
+0.09 (1.58%)
Updated Oct 4, 2024 01:29 PM ET
After-Market: $5.60 +0.07 (1.27%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
CASI Pharmaceuticals Inc. [CASI]
Reports for Purchase
Showing records 1 - 20 ( 71 total )
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Awaiting CNCT19 Dispute Resolution; Lower PT to $6; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Gearing Up for Launch of CNCT19; Higher $12PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Potential Launch of CNCT19 By Year-End Is Key for Growth; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Looking Ahead to the Launch of CNCT19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Spotlight on Expected Launch of CNCT19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Continued COVID Headwinds; Spotlight on CNCT19; Adjusting PT to $10; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Juventas Shares Sold; CNCT19 Remains a Major Upside; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Emerging From COVID Lock-Downs; Eyes on CNCT19; Adjusting PT to $12; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Continued Impact From COVID Lock-Downs; Lower PT to $3; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Revenue Growth Expected Despite Headwinds; Looking to CAR-T Readout in 2H22; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Higher Evomela Revenues and Clinical Milestones to Come in 2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Evomela Revenue Exceeds Expectations; Clinical Progress in 2022; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Evomela sales drive guidance upgrade
Provider: Edison Investment Research Limited
Analyst: Research Department
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Strong Evomela Sales Driving Higher Revenue Guidance; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Evomela and CAR-T to Drive Top-line Growth; Raise PT to $4; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Continuing to advance and expand the pipeline
Provider: Edison Investment Research Limited
Analyst: CALLOWAY N
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Company: CASI Pharmaceuticals Inc.
Industry: Medical - Drugs
Evomela Sales Beating Expectations; Continued Growth in 2021; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: LEE S